In addition, TAS-102 reported encouraging results compared with placebo in randomized phase-III study, which is a new oral nucleoside anti-tumour agent consisting of trifluorothymidine and a thymidine phosphorylase inhibitor [17]. The gene discussed is TYMP; the disease is neoplasm.